✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
pelacarsen Lp(a) trial results — Pelacarsen Lp(a) Trial Results. Read on for an evidence-backed guide covering everything you need to know.
Key Takeaways
- Lipoprotein(a) — or Lp(a) — is a genetic form of “bad cholesterol” that roughly 1 in 5 people inherit and cannot lower through diet or exercise.
- The pelacarsen Lp(a) trial results from the phase III Lp(a)HORIZON study show the drug failed to reduce heart attacks and strokes — a major setback for the first-ever Lp(a)-lowering outcomes trial.
- Pelacarsen previously showed an impressive 80% reduction in Lp(a) levels — but lowering the biomarker did not translate into fewer cardiovascular events in this trial.
- Several other Lp(a)-lowering drugs remain in late-stage trials, so the Lp(a) treatment story is far from over.
- If you have a family history of early heart disease or elevated cholesterol that statins can’t fix, an Lp(a) blood test could reveal an underlying genetic driver.
On September 4, 2026, the pelacarsen Lp(a) trial results landed — and they were not what the cardiology world had been hoping for. Novartis announced that its experimental drug pelacarsen, designed to slash levels of a genetically determined type of cholesterol called lipoprotein(a), failed to reduce heart attacks, strokes, or cardiovascular deaths in the landmark Lp(a)HORIZON trial. It was the first-ever large cardiovascular outcomes study for an Lp(a)-lowering therapy, and its failure raises big questions — not just about this drug, but about whether lowering Lp(a) itself is the right target.
Pelacarsen Lp(a) trial results — here is what makes this story different from your typical “drug fails trial” headline: the pelacarsen Lp(a) trial results do not mean Lp(a) is unimportant. Far from it. The genetic evidence linking elevated Lp(a) to heart disease is among the strongest in all of cardiovascular medicine. What these results may tell us — and we will unpack this fully — is that lowering Lp(a) needs to happen earlier, or more aggressively, or in the right patient population.
By the end of this article, you will understand what Lp(a) is, why the pelacarsen Lp(a) trial results matter for anyone concerned about heart health, and what the future holds for patients with this inherited risk factor.
Pelacarsen Lp(a) trial results: What Is Lipoprotein(a)?
Quick Answer: Lipoprotein(a) — pronounced “lipoprotein little a” and written as Lp(a) — is a type of cholesterol-carrying particle that looks like a regular LDL particle with an extra protein “tail” called apolipoprotein(a) attached to it. Unlike ordinary LDL cholesterol, Lp(a) levels are almost entirely determined by your genes and stay remarkably stable throughout your life. Diet, exercise, and even statins do very little to lower it.
Think of regular LDL cholesterol as a truck carrying fat through your bloodstream. Lp(a) is that same truck — but with a grappling hook welded to its bumper. The extra apolipoprotein(a) chain makes Lp(a) particles more likely to stick to artery walls, promote clotting, and fuel inflammation. That is why elevated Lp(a) is considered an independent risk factor for heart disease, stroke, and aortic valve narrowing — independent meaning it adds risk on top of whatever your LDL level is.
The LPA gene, which codes for apolipoprotein(a), is one of the most fascinating genes in the human genome. It evolved only in primates and varies enormously between individuals — some people make almost no Lp(a), while others produce levels 1,000 times higher. If you have high Lp(a), you were likely born with it, and it has been silently affecting your arteries for decades before anyone thought to measure it.
Understanding this biology helps explain why the pelacarsen Lp(a) trial results were so eagerly awaited: pelacarsen works by targeting the messenger RNA produced by the LPA gene, essentially telling the liver to stop making apolipoprotein(a). No apolipoprotein(a), no Lp(a) particles. It is an elegant mechanism — but as we now know, elegance does not always translate into outcomes.
Pelacarsen Lp(a) trial results: How Does Lp(a) Affect Heart Disease Risk?
Quick Answer: Elevated Lp(a) promotes atherosclerosis through three distinct pathways — it deposits cholesterol in artery walls like LDL does, it carries pro-inflammatory oxidized phospholipids that fuel plaque growth, and it interferes with the body’s natural clot-busting system because apolipoprotein(a) structurally resembles plasminogen. The result is a triple threat: more plaque, more inflammation, and a higher tendency to form dangerous blood clots.
Epidemiological data consistently show that people with Lp(a) levels above 50 mg/dL (roughly 125 nmol/L) have a significantly higher risk of myocardial infarction and ischemic stroke — and this risk is present even when LDL cholesterol is well-controlled. Genetic studies, particularly Mendelian randomization analyses, have provided perhaps the strongest evidence that Lp(a) is causally linked to cardiovascular disease, not just correlated with it.
Here is a sobering statistic: approximately 20% of the world’s population has elevated Lp(a), and most of them have no idea. Routine cholesterol panels do not measure Lp(a) — you have to ask for it specifically. This is especially concerning for people with a strong family history of early heart attacks, because inherited high Lp(a) is one of the most common genetic reasons for premature cardiovascular disease.
The pelacarsen Lp(a) trial results were designed to answer the ultimate question: if you dramatically lower Lp(a), do you prevent events? The trial enrolled patients with established cardiovascular disease and Lp(a) ≥ 70 mg/dL — a high-risk group with no targeted treatment options. The hypothesis was sound. The biomarker data from phase II was stunning. But the phase III outcomes tell a more complicated story.
What Are Pelacarsen and Antisense Oligonucleotides? — Pelacarsen Lp(a) trial results Explained
Quick Answer: Pelacarsen (also known as TQJ230 and previously AKCEA-APO(a)-LRx) is an antisense oligonucleotide — a short strand of chemically modified DNA that binds to the messenger RNA for apolipoprotein(a) and marks it for destruction. By preventing the LPA gene’s message from being read, pelacarsen dramatically reduces the liver’s production of Lp(a) particles.
Antisense oligonucleotides represent a relatively new class of medicines that work upstream of traditional small-molecule drugs. Instead of blocking a protein after it has been made, they prevent the protein from being made in the first place. In the case of Lp(a), this is particularly important because no small molecule can effectively block apolipoprotein(a) once it has been produced — there is simply no good binding pocket to target.
The phase II study of pelacarsen, published in the New England Journal of Medicine in 2020, showed that the drug reduced Lp(a) levels by approximately 80% in a dose-dependent manner. Patients received a monthly subcutaneous injection — essentially a shot under the skin, similar to how many people self-administer insulin. The safety profile appeared favorable, with injection-site reactions being the most common side effect.
These phase II results generated enormous enthusiasm, and the pelacarsen Lp(a) trial results from phase III were expected to be practice-changing. The cardiology community had been waiting decades for a drug that specifically targets Lp(a). When Novartis acquired the rights to pelacarsen and launched Lp(a)HORIZON — enrolling over 7,600 patients across more than 40 countries — it was widely seen as one of the most important cardiovascular trials of the decade.
What the Lp(a)HORIZON Trial Found
Research Spotlight: The First Lp(a) Outcomes Trial
The Lp(a)HORIZON trial (NCT04023552) was a randomized, double-blind, placebo-controlled phase III study evaluating pelacarsen 80 mg administered subcutaneously once monthly versus placebo. Patients had established atherosclerotic cardiovascular disease and baseline Lp(a) ≥ 70 mg/dL. The primary endpoint was a composite of major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization.
On September 4, 2026, Novartis announced that pelacarsen did not meet its primary MACE endpoint. While full detailed results have not yet been published or presented at a medical congress, the topline announcement confirmed that the trial failed to demonstrate a statistically significant reduction in cardiovascular events despite achieving substantial and sustained Lp(a) lowering.
Here is what we know from the phase II data that preceded these results. Pelacarsen produced an 80% median reduction in Lp(a) levels — far more than any other approach, including PCSK9 inhibitors (which lower Lp(a) by 20–30%) or niacin (roughly 20–25%). The drug appeared to work as designed at the molecular level. The disconnect between biomarker reduction and clinical benefit is the central puzzle of the pelacarsen Lp(a) trial results.
This pattern — a drug hitting its biomarker target but missing clinical endpoints — is not unprecedented in cardiovascular medicine. CETP inhibitors like torcetrapib and dalcetrapib raised HDL cholesterol but failed to reduce events. More recently, the PROMINENT trial of pemafibrate showed triglyceride lowering without cardiovascular benefit. The lesson from these precedents is that biomarker changes do not always translate into outcomes — and Lp(a) may be the latest addition to this cautionary list.
| Study Phase | Drug | Lp(a) Reduction | Primary Endpoint | Outcome |
|---|---|---|---|---|
| Phase II (NEJM 2020) | Pelacarsen | ~80% | Safety & Lp(a) levels | Met — significant Lp(a) reduction |
| Phase III Lp(a)HORIZON (2026) | Pelacarsen | Confirmed substantial lowering | MACE (CV death, MI, stroke, revascularization) | Not met |
Why Did Pelacarsen Fail? Possible Explanations
Without full trial data — which will likely be presented at a major cardiology conference in the coming months — any explanation is preliminary. But here are the leading hypotheses being discussed by researchers.
Hypothesis 1: Lp(a) is a risk marker, not a causal driver. This is the most provocative possibility. Despite strong genetic evidence from Mendelian randomization studies, it is possible that Lp(a) is a bystander — elevated in people who develop heart disease for other reasons — rather than a direct cause. If true, lowering it would not prevent events regardless of how effectively you do it. Most lipidologists consider this unlikely given the genetic data, but the pelacarsen Lp(a) trial results force us to confront it seriously.
Hypothesis 2: The absolute Lp(a) reduction was insufficient. While the relative reduction was 80%, the absolute reduction matters more biologically. If a patient starts with Lp(a) of 200 mg/dL and drops to 40 mg/dL after pelacarsen, they may still carry enough residual risk to wipe out any detectable benefit. The Lp(a) field has debated what threshold of absolute reduction is necessary — and the answer may be “lower than we achieved, for longer than we tried.”
Hypothesis 3: You need to lower Lp(a) before atherosclerosis develops. The trial enrolled patients with established cardiovascular disease — meaning their arteries were already damaged. Lp(a) exerts its effects over decades, silently contributing to plaque buildup from early adulthood. Trying to reverse that process in people who already have advanced disease may be too late. This is analogous to the “legacy effect” seen in LDL-lowering trials, where starting a statin at age 40 prevents more events than starting at 65.
Hypothesis 4: Lp(a) works through oxidized phospholipids, not the particle itself. Apolipoprotein(a) carries oxidized phospholipids — highly inflammatory molecules — and some researchers believe these, not the Lp(a) particle count, drive the cardiovascular risk. Pelacarsen lowers the whole particle, which does reduce oxidized phospholipid load, but perhaps not enough in this high-risk population.
Hypothesis 5: Competing risk from background therapy. Patients in Lp(a)HORIZON were on optimal background therapy including high-intensity statins. When everyone’s LDL is already well-controlled, it becomes harder to show incremental benefit from an additional therapy — even one that works.
What Comes Next for Lp(a) Treatment?
Quick Answer: The pelacarsen Lp(a) trial results are a setback, but they do not close the book on Lp(a)-lowering therapies. Several other drugs using different mechanisms are in advanced clinical trials, and the questions raised by Lp(a)HORIZON will shape how those trials are designed and interpreted.
Here is the current Lp(a) drug pipeline:
Olpasiran (AMG 890) — This is a small interfering RNA (siRNA) therapy developed by Amgen, currently in the phase III OCEAN(a)-Outcomes trial. Like pelacarsen, it targets LPA gene expression, but through the RNA interference pathway rather than antisense. Phase II data showed Lp(a) reductions exceeding 95% in some patients — even more than pelacarsen. OCEAN(a) is expected to read out in 2027–2028. The question everyone is asking: can a deeper and more sustained Lp(a) reduction succeed where pelacarsen failed?
Lepodisiran (LY3819469) — Eli Lilly’s siRNA candidate, also in phase III. Early data suggest similarly profound Lp(a) lowering. The cardiovascular outcomes trial is ongoing.
Muvalaplin (LY3473329) — This is the most chemically distinct candidate: a small-molecule oral drug that blocks the assembly of Lp(a) particles by preventing apolipoprotein(a) from binding to apoB. Phase II data showed approximately 65% Lp(a) reduction. An oral option would be a major advantage over injectable ASOs and siRNAs.
Zerlasiran (SLN360) — Another siRNA in earlier-stage development.
The pelacarsen Lp(a) trial results will inevitably influence the design of these ongoing trials. Statistical analysis plans may be revised. Data safety monitoring boards will scrutinize interim analyses with renewed attention. And investors — who drove significant funding into the Lp(a) space based on the genetic rationale — will recalibrate their expectations.
For patients, the message is nuanced: the Lp(a) lowering hypothesis is not dead, but it is now unproven. Anyone with elevated Lp(a) should continue aggressive management of modifiable risk factors — blood pressure, LDL cholesterol, diabetes, smoking — while the science sorts itself out.
Should You Get Tested for Lp(a)?
The pelacarsen Lp(a) trial results do not change the case for testing — in fact, they may strengthen it. Knowing your Lp(a) level gives you and your doctor critical information about your cardiovascular risk, regardless of whether a specific Lp(a)-lowering drug exists.
Current European Society of Cardiology / European Atherosclerosis Society guidelines recommend measuring Lp(a) at least once in everyone’s lifetime, particularly for risk stratification. The pelacarsen Lp(a) trial results do not invalidate this recommendation — if anything, understanding your Lp(a) level matters more now, because it helps you and your doctor assess whether you fall into a risk category that might benefit from aggressive management of all other cardiovascular risk factors. This is because Lp(a) is stable over time — one test, one number, one lifelong risk factor.
Consider getting an Lp(a) test if you are concerned about how the pelacarsen Lp(a) trial results might affect your personal risk assessment:
- You have a parent or sibling who had a heart attack or stroke before age 55 (men) or 60 (women)
- You have had a cardiovascular event yourself despite normal LDL cholesterol
- Your LDL stays stubbornly high even on maximum statin therapy
- You have aortic valve stenosis or a family history of it
- You are simply proactive about understanding your full cardiovascular risk profile
The test is a standard blood draw and is available through most commercial laboratories. In many countries, it costs roughly the same as a standard lipid panel. You do not need to fast before the test.
If your Lp(a) comes back elevated — typically defined as above 50 mg/dL or 125 nmol/L — your doctor may recommend more aggressive LDL lowering, as statins can reduce overall cardiovascular risk even though they do not lower Lp(a) itself. Some guidelines also suggest considering low-dose aspirin in selected high-risk patients with elevated Lp(a), though this is an individualized decision.
Frequently Asked Questions
Q: What are the pelacarsen Lp(a) trial results in simple terms?
A: The pelacarsen Lp(a) trial results show that the drug pelacarsen successfully lowered lipoprotein(a) levels by about 80% but did not reduce heart attacks, strokes, or cardiovascular deaths compared to placebo in people with existing heart disease. This was the first large trial testing whether lowering Lp(a) prevents cardiovascular events, and it did not meet its primary goal. The full data has not yet been published.
Q: Can you lower Lp(a) with diet or exercise?
A: No. Lp(a) levels are almost entirely determined by your LPA gene. Unlike LDL cholesterol, which responds to dietary changes, exercise, and weight loss, Lp(a) stays remarkably consistent throughout your life regardless of lifestyle interventions. This is one reason Lp(a) is considered a distinct and independent cardiovascular risk factor.
Q: Do statins lower Lp(a)?
A: Statins do not lower Lp(a) — in fact, some studies suggest they may slightly increase it. However, statins still reduce overall cardiovascular risk in people with elevated Lp(a) by lowering LDL cholesterol and stabilizing plaques. The net benefit of statin therapy outweighs any theoretical concern about a small Lp(a) increase.
Q: Is Lp(a) the same as LDL cholesterol?
A: No. Lp(a) is a distinct particle that contains an LDL-like core plus an additional protein chain called apolipoprotein(a). While standard LDL cholesterol tests capture some Lp(a)-carried cholesterol (because Lp(a) particles contain LDL), the Lp(a) particle itself has unique properties that make it more dangerous — it is more inflammatory and more likely to promote blood clotting than ordinary LDL.
Q: How common is elevated Lp(a)?
A: Approximately 20% of the global population — one in five people — has Lp(a) levels above 50 mg/dL, the threshold generally considered elevated. Prevalence varies by ethnicity: people of African descent tend to have the highest levels, while East Asian populations tend to have lower median levels. Most people with elevated Lp(a) are unaware of it.
Q: Will there ever be an approved drug to lower Lp(a)?
A: The pelacarsen Lp(a) trial results are a setback, but they do not end the search. Several other drugs — including olpasiran, lepodisiran, and muvalaplin — are in phase III trials using different mechanisms. If any of these succeed in an outcomes trial, an Lp(a)-lowering drug could still reach the market. Realistically, the soonest this could happen is 2028–2030.
Q: What should I do if my Lp(a) is high?
A: Focus on aggressively managing the risk factors you can control. This means keeping LDL cholesterol as low as possible (your doctor may set a lower LDL target for you), controlling blood pressure, not smoking, maintaining a healthy weight, and staying physically active. Some doctors also recommend low-dose aspirin for selected patients with very high Lp(a), but this must be individualized because aspirin carries its own bleeding risk.
Q: How is Lp(a) different from ApoB?
A: ApoB (apolipoprotein B) is a protein found on all atherogenic lipoprotein particles — LDL, VLDL, IDL, and Lp(a). Measuring apoB gives you the total count of all these dangerous particles. Lp(a) is a specific type of particle that includes apoB plus the extra apolipoprotein(a) chain. Both tests are valuable: apoB gives you a broader picture of your atherogenic particle burden, while Lp(a) identifies a specific genetically driven risk that apoB alone may not fully capture.
The Bottom Line
The pelacarsen Lp(a) trial results are disappointing but not devastating. They remind us that cardiovascular medicine is littered with promising biomarkers that did not translate into clinical benefit when targeted — CETP inhibitors for HDL, pemafibrate for triglycerides, and now, at least for this specific drug in this specific population, Lp(a) lowering with pelacarsen. But the genetic evidence linking Lp(a) to heart disease remains robust, and multiple drugs with different mechanisms are still in the pipeline. The long-term implications of the pelacarsen Lp(a) trial results will take years to fully understand.
If you take one action after reading this article, let it be this: if you have not had your Lp(a) checked and you have a family history of early heart disease, ask your doctor about the test at your next visit. It is a once-in-a-lifetime measurement that costs roughly the same as a standard cholesterol panel — and it could uncover a hidden genetic driver of heart disease that you never knew you had.
Wondering whether statins alone are enough to manage your cholesterol risk? Read our guide on statin intolerance and what to do when statins aren’t working. Interested in the full picture of heart disease prevention? Browse our Cholesterol & Lipids education hub.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your doctor before making decisions about testing, treatment, or medication. Pelacarsen is an investigational drug and is not approved by any regulatory agency.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.